Overview

A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the superiority of inhibitory effects and safety of Menatetrenone (E0167) on recurrence in patients with hepatocellular carcinoma.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Eisai Limited
Treatments:
Menatetrenone
Vitamin K 2